Vertex EVP Joy Liu sells 892 shares at $495.96

Vertex Pharmaceuticals executive Joy Liu sold shares under a pre‑planned program.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Joy Liu sold shares under a pre‑planned program. On March 2, 2026, she completed an open-market sale of 892 shares of Vertex common stock at $495.96 per share. After this transaction, she directly held 22,811 Vertex shares. The sale was made under a company-approved Rule 10b5‑1 trading plan entered into on November 25, 2025.

Insider Trade Summary

Net Seller: 892 shares

Net Sell 1 txn

Insider Liu Joy

Role EVP and Chief Legal Officer

Sold 892 shs ($442K)

Type	Security	Shares	Price	Value
Sale	Common Stock	892	$495.96	$442K

Holdings After Transaction: Common Stock — 22,811 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vertex (VRTX) executive Joy Liu report in this Form 4 filing?

Joy Liu reported an open-market sale of Vertex common stock. She sold 892 shares on March 2, 2026, at $495.96 per share and continued to hold 22,811 shares directly after the transaction.

How many Vertex (VRTX) shares did Joy Liu sell and at what price?

Joy Liu sold 892 shares of Vertex common stock. The shares were sold at a price of $495.96 per share in an open-market transaction on March 2, 2026, as disclosed in the Form 4 filing.

How many Vertex (VRTX) shares does Joy Liu hold after this transaction?

After the reported sale, Joy Liu directly holds 22,811 Vertex common shares. This figure reflects her direct ownership immediately following the 892-share open-market sale disclosed in the Form 4 insider trading report.

Was Joy Liu’s sale of Vertex (VRTX) shares part of a Rule 10b5-1 trading plan?

Yes, the sale was executed under a company-approved Rule 10b5-1 trading plan. The footnote states the plan was entered into on November 25, 2025, providing a pre-arranged schedule for selling shares.

What is Joy Liu’s role at Vertex (VRTX) mentioned in the Form 4?

The Form 4 identifies Joy Liu as an officer of Vertex, serving as Executive Vice President and Chief Legal Officer. This role classifies her as an insider required to report transactions in company stock.

What type of transaction did Joy Liu report for her Vertex (VRTX) shares?

She reported an open-market sale of common stock. The transaction code was “S,” described as a sale in an open market or private transaction, covering 892 shares at $495.96 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Joy

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		892	D	$495.96	22,811	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.